The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties.
暂无分享,去创建一个
M. Toungouz | M. Najar | L. Lagneaux | D. Bron | B. Stamatopoulos | N. Meuleman | C. De Bruyn | G. Raicevic
[1] M. Najar,et al. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. , 2011, Stem cells and development.
[2] D. Meldrum,et al. TLR4 Inhibits Mesenchymal Stem Cell (MSC) STAT3 Activation and Thereby Exerts Deleterious Effects on MSC–Mediated Cardioprotection , 2010, PloS one.
[3] W. Weimar,et al. Inflammatory conditions affect gene expression and function of human adipose tissue‐derived mesenchymal stem cells , 2010, Clinical and experimental immunology.
[4] E. Lombardo,et al. Modulation of Adult Mesenchymal Stem Cells Activity by Toll-Like Receptors: Implications on Therapeutic Potential , 2010, Mediators of inflammation.
[5] J. Mitchell,et al. Innate Immunity in Human Embryonic Stem Cells: Comparison with Adult Human Endothelial Cells , 2010, PloS one.
[6] S. Akira,et al. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.
[7] Michael D. George,et al. Inflammation Anergy in Human Intestinal Macrophages Is Due to Smad-induced IκBα Expression and NF-κB Inactivation* , 2010, The Journal of Biological Chemistry.
[8] P. Martiat,et al. Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. , 2010, Human immunology.
[9] Shilpa Shankar,et al. Pro-Inflammatory Cytokines, IFNγ and TNFα, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells Differentially , 2010, PloS one.
[10] S. Lang,et al. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells. , 2010, Stem cells and development.
[11] M. Netea,et al. Toll-like receptor triggering in cord blood mesenchymal stem cells , 2009, Journal of cellular and molecular medicine.
[12] E. Lombardo,et al. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. , 2009, Tissue engineering. Part A.
[13] R. Romieu-Mourez,et al. Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.
[14] M. Weller,et al. Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R , 2009, Stem cells.
[15] C. Laflamme,et al. Impact of Anti-Inflammatory Agents on the Gene Expression Profile of Stimulated Human Neutrophils: Unraveling Endogenous Resolution Pathways , 2009, PloS one.
[16] F. Farina,et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers , 2009, Histochemistry and Cell Biology.
[17] Manuel A. González,et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis , 2009, Annals of the rheumatic diseases.
[18] P. Wernet,et al. Unrestricted Somatic Stem Cells from Human Umbilical Cord Blood Can be Differentiated into Neurons with a Dopaminergic Phenotype , 2008 .
[19] R. Zhao,et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. , 2008, Cell stem cell.
[20] L. Cosmi,et al. Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.
[21] Ruth S. Waterman,et al. Toll‐Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses , 2008, Stem cells.
[22] L. Ortiz,et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.
[23] R. Tuan,et al. Comparison of Proliferative and Multilineage Differentiation Potential of Human Mesenchymal Stem Cells Derived from Umbilical Cord and Bone Marrow , 2007, Stem cells.
[24] Y. Bae,et al. Role of Toll‐Like Receptors on Human Adipose‐Derived Stromal Cells , 2006, Stem cells.
[25] R. Yañez,et al. Adipose Tissue‐Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft‐Versus‐Host Disease , 2006, Stem cells.
[26] A. Yoshimura,et al. Two-Sided Roles of IL-27: Induction of Th1 Differentiation on Naive CD4+ T Cells versus Suppression of Proinflammatory Cytokine Production Including IL-23-Induced IL-17 on Activated CD4+ T Cells Partially Through STAT3-Dependent Mechanism1 , 2006, The Journal of Immunology.
[27] A. Uccelli,et al. Immunoregulatory function of mesenchymal stem cells , 2006, European journal of immunology.
[28] Qingbo Xu,et al. TLR4 expression in mouse embryonic stem cells and in stem cell-derived vascular cells is regulated by epigenetic modifications , 2006 .
[29] R. Willemze,et al. Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-Derived and Monocyte-Derived Dendritic Cells1 , 2006, The Journal of Immunology.
[30] Hermann Eichler,et al. Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue , 2006, Stem cells.
[31] C. Kao,et al. Structural and Functional Analyses of the Human Toll-like Receptor 3 , 2006, Journal of Biological Chemistry.
[32] L. Pénicaud,et al. Immunomodulatory effect of human adipose tissue‐derived adult stem cells: comparison with bone marrow mesenchymal stem cells , 2005, British journal of haematology.
[33] D. Mevorach,et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.
[34] M. Pittenger,et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.
[35] A. Iwasaki,et al. Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.
[36] J. Kirkwood,et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. , 2004, Cancer research.
[37] Wei Zhang,et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. , 2004, Stem cells and development.
[38] H. Klüter,et al. Critical Parameters for the Isolation of Mesenchymal Stem Cells from Umbilical Cord Blood , 2004, Stem cells.
[39] R. Willemze,et al. Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. , 2003, Experimental hematology.
[40] O. Ringdén,et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.
[41] T. Mak,et al. Cutting Edge: Role of IL-27/WSX-1 Signaling for Induction of T-Bet Through Activation of STAT1 During Initial Th1 Commitment1 , 2003, The Journal of Immunology.
[42] Elizabeth Simpson,et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.
[43] E. Guinan,et al. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.
[44] O. Ringdén,et al. Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.
[45] A. Griesmacher,et al. Endothelial adhesion molecule expression in an in vitro model of inflammation. , 2002, Clinica chimica acta; international journal of clinical chemistry.
[46] H. Lorenz,et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. , 2001, Tissue engineering.
[47] V. Appay,et al. RANTES: a versatile and controversial chemokine. , 2001, Trends in immunology.
[48] V. Appay,et al. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. , 2000, International immunology.
[49] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[50] K. Matsushima,et al. Essential involvement of interleukin‐8 (IL‐8) in acute inflammation , 1994, Journal of leukocyte biology.
[51] R. Strieter,et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.
[52] Y. Watanabe,et al. Gap-junctional communication of bone marrow stromal cells is resistant to irradiation in vitro. , 1990, Experimental hematology.
[53] P. Dörmer,et al. Haemopoietic Inductive Capacity of Irradiated Stromal Cell Layers In Human Micro Long‐Term Bone Marrow Cultures , 1988, Cell and tissue kinetics.
[54] M. Toungouz,et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. , 2010, Cellular immunology.
[55] H. Koo,et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. , 2009, Cellular immunology.
[56] P. Martiat,et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. , 2009, Cytotherapy.
[57] L. Fouillard,et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. , 2008, Cellular immunology.
[58] Kazuya Sato,et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.
[59] F. Benvenuto,et al. Human mesenchymal stem cells modulate B-cell functions. , 2006, Blood.
[60] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.